Medtech and pharmaceutical companies have made several important strides over the past year when it comes to improving diabetes treatment. Multiple treatments and technologies have cleared regulatory hurdles and are now hitting the market and making the process of living with diabetes that much more manageable. Several different styles of therapy and devices have come […]
Insulet wins FDA nod for Omnipod with Novo Nordisk’s Fiasp insulin
Insulet (NSDQ:PODD) said last week that it won FDA clearance for the use of Novo Nordisk‘s (NYSE:NVO) Fiasp insulin with the Omnipod insulin management platform. Acton, Mass.-based Insulet said it completed extensive testing to ensure that Fiasp is safe and usable with the Omnipod and Omnipod Dash systems. It’s the first insulin pump in the U.S. […]
Abbott, Medtronic ink diabetes pacts with Sanofi, Novo Nordisk
Abbott (NYSE:ABT) and Medtronic (NYSE:MDT) today announced separate data-sharing deals for digital diabetes management solutions. Abbott is partnering with Sanofi (NYSE:SNY) to integrate glucose sensing and insulin delivery to help people manage their diabetes. The two companies plan to develop tools to combine Abbott’s FreeStyle Libre technology with insulin dosing information for smart pens, insulin titration apps and […]
Novo Nordisk seeks FDA nod for oral diabetes pill
Novo Nordisk (NYSE:NVO) said this week that it submitted applications to the FDA for its oral formulation of semaglutide, a once-daily glucagon-like peptide-1 receptor agonist therapy. The company is hoping its pill will be approved as an adjunct to diet and exercise to improve blood sugar control in adults with Type 2 diabetes. Novo Nordisk also […]
Glooko, Novo Nordisk team up for connected insulin pens
Glooko announced this month that it’s teaming up to connect Novo Nordisk‘s (NYSE:NVO) insulin pens with the company’s diasend diabetes management solution. Novo Nordisk plans to launch its connected insulin pens, the NovoPen 6 and NovoPen Echo Plus, in early 2019. Any provider using diasend and any person using the diasend mobile app will be able […]
Abbott, Novo Nordisk ink deal for digital diabetes tools
Abbott (NYSE:ABT) said today that it inked a non-exclusive deal to integrate insulin dose data from Novo Nordisk‘s (NYSE:NVO) pre-filled and connected pens with its FreeStyle Libre mobile app and cloud-based system. The companies touted that integrating the products will allow healthcare professionals, caregivers and users to easily view glucose and insulin data, as well as […]
Study: Researchers develop ingestible capsule for insulin delivery
A team of researchers from MIT developed an ingestible, blueberry-sized capsule that can deliver insulin orally. In animal models, the capsule lowered blood sugar levels and performed comparably with the traditional route of insulin delivery – injections. The capsule features a small needle made of freeze-dried, compressed insulin. The needle is attached to a compressed […]
Pharma stocks fall as Rep. Cummings launches drug pricing investigation
Chairman of the House Oversight Committee Rep. Elijah Cummings (D-MD) launched an investigation today into the drug pricing practices of 12 pharmaceutical companies. A number of companies named in the investigation saw their stock prices fall, including Amgen (NSDQ:AMGN), AbbVie (NYSE:ABBV), AstraZeneca (NYSE:AZN), Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO). A hearing is reportedly set for Jan. 29 and will […]
Novo Nordisk partners with Flex for digital diabetes management tools
Flex (NSDQ:FLEX) today announced a partnership with Novo Nordisk (NYSE:NVO) to develop digital diabetes management tools using Flex’s BrightInsight IoT platform. Novo Nordisk plans to use Flex’s BrightInsight system to build and manage connected medical devices and the corresponding data. The company’s IoT platform is designed to enable organizations to develop digital health devices while remaining […]
Anthem, Novo Nordisk team up for real-world diabetes drug study
Anthem’s outcomes research unit, HealthCore, and Novo Nordisk (NYSE:NVO) have joined forces to study Novo Nordisk’s semaglutide GLP-1 receptor agonist in people with Type 2 diabetes. The real-world trial is designed to compare the long-term effectiveness of the drug, also known as Ozempic, against 40 other medications among 2,250 adults with Type 2 diabetes. “Because the Sepra […]
- 1
- 2
- 3
- …
- 7
- Next Page »
Drug Delivery Business News
@DrugDeliveryNow
LinkedIn